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What was accomplished under these goals?
Aim 1: Cytokine, cardiac marker, and growth factor testing: Testing was performed on 100 of 100 planned subjects from the ABLE trial. For the vast majority of analytes, no differences were seen between the two treatment groups (fresh vs. standard issue blood), consistent with the clinical findings of the parent trial. We are still blinded to groups so do not know which group received fresh blood. At day 28 post-transfusion group 2 subjects had marginally higher levels of IL-2 and IFN-γ, though these changes would not be significant after correction for multiple comparisons. Once the clinical data become available the cytokine data will be correlated with outcomes. There is modulation of some cytokines over time, such as IL-6 and IL-8. We anticipate that pairing these data with clinical outcomes will provide insight into the role of inflammation in ICU patient outcomes.
What opportunities for training and professional development has the project provided?
How were the results disseminated to communities of interest?
What do you plan to do during the next reporting period to accomplish the goals?
Nothing to Report
To date, two manuscripts have been published (see below). This is a preliminary (interim) final report. We still have plans to disseminate the results of our studies, as analyses are still being completed. We will present the findings in peer-reviewed publications and at national and international scientific conferences.


Technologies or techniques
Inventions, patent applications, and/or licenses
As part of this program our group made significant advances in how to quantitate and characterize extracellular vesicles. These data have been published in peer-reviewed journals.
None
ing EVs have been shown to promote tumor progression by suppressing immune function (15 19 ) and supporting tumor cell migration in metastasis (20 23) , while others have been shown to suppress disease progression by conferring therapeu tic benefit in the treatment of diseases such as ischemia (24) and kidney disease (25) . Clinically, EVs have a wide range of applications in diagnostics and disease therapy. EVs in biolog ical fluids can be monitored for disease biomarkers, as con centrations of some EVs are known to be associated with increased risk of specific diseases and cancers, including lym phoma (26) , lung (27) , breast, gastric (28) , colorectal, pros tate, kidney, and ovarian cancer (29 33) and cardiovascular disease (34) . In addition to their use in disease monitoring, some researchers are utilizing EVs to develop new treatments and anticancer therapies. The roles of certain EV subtypes to inhibit tumor growth has been investigated as a potential treatment for cancer (35, 36) . More recently, researchers have shown that EVs can be manipulated to deliver tailored thera peutic cargo to specific targets within the body (37, 38) . A number of methods have been used to analyze EVs, including scanning electron microscopy (39, 40) , transmission electron microscopy (TEM) (41) , atomic force microscopy and dynamic light scattering (42 45) , and western blotting (46, 47) . Clinically, flow cytometry (FCM) is the most com monly used method for analyzing EVs in blood (5,48 50) ; however, accurate characterization of EVs remains challeng ing. Perhaps some of the most significant problems associated with measuring EVs using FCM stem from the ability/sensitiv ity of this method to properly discriminate positive from neg ative events. This is due mainly to the small size of the EVs, which results in (1) less fluorescence emitted due to the fewer number of antigens per particle and (2) limited feasibility of post stain washing to reduce background fluorescence. Fur thermore, because FCM uses a triggering threshold to initiate a signal, electronic noise and particulates in the sheath and sample buffer can generate very high background signals, which can drown out/overwhelm very small signals created by EVs. Using a side scatter threshold, researchers have reported being able to differentiate 100 nm from 300 nm beads (48) , however, EVs have a lower refractive index than beads which limits their detection at these lower limits. Some researchers prefer to use a fluorescent channel as the triggering threshold (51) , however, this is complicated by the fact that no pan specific marker for all EVs exists. Annexin V, once considered to be a robust EV marker by binding to EV surface phosphati dylserine (PS), has more recently been shown to fail to bind to the majority of EVs (52, 53) , with binding being greatly affected by calcium concentrations and pre analytical condi tions (54) . Therefore, while specific subpopulations may be better detected using a fluorescence threshold, all other subpo pulations (those not carrying the fluorescent marker) will not be detected using this method. When analyzing very small particles, accuracy depends on the proper discrimination of EVs from other non cell derived particles and on thorough removal of background noise. Prior publications have noted difficulties associated with using FCM to analyze EVs, includ ing false positive signals arising from EV mimicking immune complexes (55, 56) , self aggregation of antibodies due to agita tion (57) , and limited applicability of traditionally used FCM controls such as FMO (fluorescence minus one) and/or anti body isotypes (58) . EV sample collection and processing is yet another area in which standardization is needed, yet no con sensus exists on an optimal protocol (59 61). Many different pre analytical variables have been shown to affect EV content, including storage temperature and duration (62, 63) , anticoa gulant/preservative used (62, 64) , and centrifugation method used (59, 63) . Specialized techniques and optimized protocols have been recommended (61) ; however, there is no consensus on the best method for EV detection by FCM.
Our laboratory is performing flow cytometric analyses of the circulating EV concentration and phenotype in critically ill patients transfused with blood stored for short vs. standard storage periods. Faced with a high volume of samples to test, we needed to refine our protocol in a way that would both minimize processing time and maximize accuracy and effi ciency. Here, we present the results of EV optimization studies that were performed on healthy controls to ensure the accu racy and efficiency of EV analysis before quantifying EVs in plasma from study subjects. Our optimization experiments focused on four key areas: removal of aggregated fluorochrome conjugated antibodies prior to EV staining, washing of EVs after staining, the optimal control sample to use as the basis of setting gates to count positive EV events, and the effect of EV concentration on EV quantitation and the proportion of positive events measured.
MATERIALS AND METHODS
Study Subjects
Study samples were obtained from subjects in the Age of Blood Evaluation (ABLE) trial (65) . Intensive care unit (ICU) patients were randomly assigned to receive either fresh (< 7 days' storage) or standard (expected mean % 21 days' storage) blood for transfusion. Whole blood was collected from these patients on Day 0 (before transfusion) and on Days 2, 6, and 28 post transfusion. Some optimization steps were performed using samples from discarded Trima leukoreduction system chambers (LRSCs) from Blood Centers of the Pacific or from whole blood collected from six healthy volunteers in citrate tubes. All human subject samples were tested under an institu tional review board (IRB) approved protocol and with informed consent of the subjects.
EV and Cell Processing
EVs were isolated from whole blood using a common dif ferential centrifugation technique described in the literature (59,66 68) . Immediately after collection, tubes were centri fuged at 1,500g for 10 min to separate cells from the superna tant, then at 13,000g for 10 min to remove platelets. The supernatant was carefully removed, and this platelet poor plasma (PPP) was used to study EV concentration and pheno type. PPP from six normal donors was combined to create a normal donor pool. Aliquots of 0.5 mL were stored at 80 C (refer to Fig. 1A for overview) . Some optimization steps used EVs which had been concentrated using an additional Technical Note centrifugation or filtration step. In these instances, the EVs are referred to as "concentrated" in figure legends. When centrifu gation was used to concentrate EVs, 3 mL of PPP was added to 32 mL phosphate buffered saline (PBS, UCSF Cell Culture Facility, San Francisco, CA) and spun for 60 min at 100,000g. EV pellets were re suspended in 1 mL RPMI 1640 (Invitro gen, Carlsbad, CA) and stored at 80 C. When filtration was used to concentrate EVs, 1.5 mL of PPP was added to centrif ugal filters and resuspended in 400 mL PBS for immediate analysis (see below for full filtration method protocol). Peripheral blood mononuclear cells (PBMCs) were isolated from Trima LRSCs on a Ficoll Paque PLUS density gradient (GE Healthcare Bio Sciences, Piscataway, NJ). Aliquots of 20 3 10 6 cells were frozen in media that contained 90% fetal bovine serum (HyClone, Logan, UT) and 10% dimethyl sulf oxide (Fisher Bio Reagents, Pittsburgh, PA) and stored in liq uid nitrogen vapor.
Antibodies
In order to examine EVs for cell of origin markers (phe notype) and immune or coagulation activation markers, we used several different fluorochrome conjugated monoclonal antibodies, including red blood cell markers: CD108 PE and CD235a FITC, a platelet marker: CD41a PerCP/Cy5.5, and leukocyte markers: CD3 PerCP/Cy5.5, CD19 Alexa700, CD28 FITC, CD16 V450, CD152 APC, CD14 APC/Cy7, and CD62 L APC. All isotype controls were matched to their respective antibodies according to their fluorochrome type, concentration, heavy chain (IgA, IgG, IgD, IgE, or IgM), sub class, and light chain class (kappa, lambda). Refer to Table 1 for a detailed summary of the antibodies that were used in the experiments described in this article.
Antibody Labeling
PPP samples were rapidly thawed and 50 or 100 mL were added to 2 5 mL of each monoclonal antibody. Prior to testing EV samples, each antibody was titrated using serial dilutions to determine the "saturating" concentration (the lowest con centration which yielded nearly maximal fluorescence). Sam ples were incubated at 4 C for 30 min and either filtered or re suspended in 400 mL PBS for immediate FCM analysis.
Absolute Count Analysis
Trucount TM tubes (BD Biosciences, San Diego, CA) with a known number of fluorescent beads were utilized for EV quantification. To each Trucount tube, 50 mL sample and 350 mL PBS were added and samples were read immediately on the flow cytometer. EV concentrations were calculated using the following equation: Table 2 . Flow cytometer setup was performed using CS&T instrument setup beads (BD Biosciences). Forward scatter (FSC) and side scatter (SSC) parameters were set to log mode and the lowest threshold allowed by the cytometer (200) was selected for each. Compen sation setup was performed using AbC beads (Invitrogen) and compensation values were determined by FACS Diva software. FSC/SSC voltages were set to the highest values that excluded the majority of background noise (i.e., just below the voltage threshold at which event rate surpassed 5 events/sec while run ning a tube of PBS alone). Typically, this threshold occurred at FSC and SSC voltages of around 500 600 and 300 350, respec tively. Rainbow fluorescent particles (Spherotech, Lake Forest, IL) were used to adjust all channel voltages between batches in order to maintain voltage consistency from run to run. Figure  1B shows the location of the EV gate in relation to 0.2, 0.24, 0.5, and 1 mm beads (0.5 mL of Megamix Plus SSC; BioCytex, Mar seille, France) beads combined with 1 2 drops of Spherotech Ultra Rainbow Fluorescent Particles). These beads cannot be used to determine EV size but are useful for showing the rela tive sizes of EVs detected. All samples were acquired at low sam ple pressure and low flow rate ($8 12 mL/min). In pre optimization experiments ( Fig. 2 and Supporting Information Figs. 1 and 2) , collection of 100,000 events was attempted for each sample, and in situations with very few events, tubes were run for at least 3 min. Post optimization, each sample (includ ing lysed samples) was run for exactly 1 or 2 min to allow for the subtraction of false positive events detected in the lysed sam ple over an equal time frame. FCS files were exported and data were evaluated using FlowJo software (TreeStar, Ashland, OR; Mac version 9.6.1 or PC version 7.6.5).
Transmission Electron Microscopy
TEM was used to visualize antibodies using negative staining. Approximately 10 mL of each sample was added to a Formvar coated 300 mesh copper grid and allowed to adhere for 2 min at room temperature. Excess liquid was removed by blotting the edge of the grid with filter article. Next, a drop of 2% aqueous uranyl acetate solution was applied to the grid for 30 sec. The excess stain was removed as before and the speci mens were examined by TEM using a JEOL JEM 1400 elec tron microscope.
Lysis Step
In order to discriminate between EVs and protein aggre gates, we used a lysis technique similar to that described by Gy€ orgy et al. (55) to reveal false positive events. A non ionic detergent, 10% Nonidet P 40 (NP 40) (New England Biolabs, Ipswich, MA) was used to lyse EVs. After an initial reading on the flow cytometer, stained EV samples were added to 20 mL of 10% NP 40 (final concentration 0.5% NP 40). Samples were then re read and compared to the initial reading. Antibody positive events remaining in the lysed sample were subtracted from the positive events in the initial reading to determine the proportion of true EVs.
Filtration
Antibody filtration was performed prior to staining using Ultrafree V R MC/Durapore V R PVDF centrifugal filter units of various pore sizes (0.1, 0.22, 0.45, and 0.65 mm, Millipore, Bedford, MA). For each panel, titrated antibodies (2 5 mL each) were combined and added to the top of a filter, the tube was centrifuged in a fixed angle single speed microcentrifuge (Fisher Scientific, Pittsburgh, PA) for $ 30 sec, and the filtrate was used for staining. Post stain filtration was performed using the same filters and same filtration process, however, the filtrate was discarded and EVs remaining on the filter surface were resuspended in 400 mL PBS and saved for flow analysis. Originally, post stain filtration was performed at 600g for 30 sec. After testing a variety of PPP samples, it was ultimately decided that an increase to 800g for 2 5 min would be neces sary to accommodate all PPP samples, some of which required a slightly higher force to move through the filter effectively. Technical Note
Statistical Analysis
Nonlinear regression analysis using a semi log line was used to assess the correlation between EV concentration and percentages of antibody positive events. The two way ANOVA test followed by Tukey's multiple comparisons test was used to evaluate differences in the percentages of CD14 1 events after different sized filters were used to remove anti body aggregates in EVs and PBMCs. For EV dilution experi ments, slopes were determined by nonlinear regression analysis using a log log line, and R squared values were deter mined by nonlinear regression analysis using a log log line and slope constraint equal to 1.0 in order to assess goodness of fit. The t test corrected for multiple comparisons using the Holm Sidak method was used for comparing the Technical Note numbers of antibody positive events remaining after filtra tion or centrifugation was used to remove antibody aggre gates. The two tailed t test for paired comparisons was used to compare the mean percentages of antibody positive events before and after post stain filtration. Statistical significance was defined as P < 0.05. All statistical analyses were per formed using Prism 5 (GraphPad Software, La Jolla, CA).
RESULTS AND DISCUSSION
Antibody Aggregates Fall Within the EV FSC/SSC Gate PPP was isolated from clinical study or normal donor patient samples using a differential centrifugation process commonly found in the literature (59,66 68) (Fig. 1A) . Some of the larger EVs may have been removed with the relatively long duration centrifugation that we used. The general techni ques we describe in this article, however, are applicable to all FCM analysis of EVs and not specific to EVs derived from PPP. Samples were then stained with one or more antibody conjugated fluorochromes. When ABLE study samples were tested, which varied widely in EV concentration (EV/mL), a negative correlation between EV concentration and the pro portion positive for cellular markers was found. The samples taking the longest to acquire 100,000 events on the cytometer, i.e., samples having the lowest EV concentrations, had the highest background and thus the highest number of positive events. Supporting Information Figure 1A shows the results of EV analysis of two representative donors, one with a low con centration of EVs (top row) and one with a high concentra tion (bottom row). Plotting results from all donors revealed a significant negative correlation between EV concentration and positive events for four markers (Supporting Information  Fig. 1B ). To test whether the positive events could be due to artifact, antibody alone in PBS (without EVs added) was tested, and the same pattern of positive events was observed as in the samples having low EV concentration (Supporting Information Fig. 1C ). Since the antibody without EV sample showed more signal than the antibody with EV, this suggested that the signal was artifactual.
Eliminating Antibody Aggregates
To eliminate false positive events, the efficacy of filters to remove presumed antibody aggregates from the EV gate was tested. We experimented using several different sized filters (0.1, 0.22, 0.45, and 0.65 mm) and found that all filters were highly effective at removing aggregates without compromising the antibody's ability to stain PBMCs (Fig. 2) . Next, to deter mine the most suitable method for removing antibody aggre gates, we compared our filtration method against a common centrifugation method found in the literature (17,000g for 5 min) (69) . Filtration was more effective than centrifugation at removing aggregates from all antibodies tested, and this was confirmed by electron microscopy (Supporting Information  Fig. 2 ). Of note, longer centrifugation times than we used in the current experiments have been described (69), but we only tested a 5 min centrifugation in the current work in an attempt to develop a protocol suited to high throughput sam ple analysis. Similar 5 min centrifugation protocols to remove antibody aggregates were recommended by other researchers as well, including 16,000g for 5 min (70) and 18,000g for 5 min (63) . Antibodies filtered with smaller pore sizes were equally as effective as those filtered with larger pore sizes. We did not experience problems with clogging of the filters using any pore size during antibody filtration. One drawback to using filters for antibody aggregate removal is the cost; the retail price of each filter is $$2. However, because all antibod ies can be combined in one tube before filtering, if 40 samples were run per batch, the cost would be 5 cents per sample. In batched analyses, the filter for removing antibody aggregates comprises a small fraction of the total cost of testing each sample.
EV Gating Strategies
The final step in successfully analyzing FCM data is set ting gates to separate positive from negative events. Many researchers use isotypes to do this (60, 71, 72) , though a lysis method for identifying false positive EV events has been described (55, 56) . The lysis step utilizes a detergent to disrupt EVs, with immune complexes and other non EV related events remaining after detergent lysis eliminates the EVs. In Technical Note samples with paired lysed and unlysed samples, the lack of a true EV population expressing CD16 can be appreciated (Sup porting Information Fig. 3A) . After optimizing the use of a lysis step, lysed samples were compared to isotype stained samples for setting background fluorescence gates (Supporting Information Fig. 3B ). In these examples the donor's lysed sample was superior to the isotype control for defining back ground fluorescence for the CD235a and CD41a antibodies because the background more closely matched that of the fully stained Ab sample. Similarly, Figure 3 shows the ability of three different negative controls (FMO, isotypes, and lysed) to accurately predict the background fluorescence of a fully stained, non post stain filtered sample. FMO controls pro vided an appropriate indication of background fluorescence Gates for each marker were made using the lysed sample (top row) and then copied to the rows beneath. Green check marks indicate instances in which the background fluorescence appropriately matches that of the corresponding marker in the fully stained sample, while the red X's denote controls which poorly predicted the background fluores cence in the fully stained sample.
Technical Note (55, 56, 60, 71, 72) . However, our attempts to replicate the background of an antibody with its isotype proved to be difficult, as it was impossible to know whether the signal was true background or simply an artifact caused by the differences in spectral properties between the two stains. Indeed, a number of publications have noted similar issues associated with using isotype controls for this purpose (58, 59) . Isotype gates can vary widely depending on a number of factors including: antibody supplier, fluorochrome:protein ratio, antibody concentration, propensity for aggregation, and antibody subclass (7, 48, 58) . Though these variables can be accounted for/controlled to a certain degree, it is difficult if not impossible to match perfectly the background fluores cence of a fluorochrome conjugated antibody to that of its isotype. Considering the low number of antigens per EV (and correspondingly small fluorescence signal emitted), even minute differences in background signal between an antibody and its isotype will significantly affect proper gate placement and the ability to accurately distinguish positive events. Of all of the controls we tested (FMO, unstained, isotype, and lysed), lysed samples proved to be the most consistently reli able as an indicator of background fluorescence across all markers when samples were left unwashed after staining. Other researchers have reported the use of antigen negative EVs as negative controls for setting background fluorescence gates (58) . However, because background fluorescence can often vary from individual to individual, it may be inappro priate to apply the gates created from a single sample of entirely different origin to all clinical samples in the study. Furthermore, this method requires the use of twice the amount of antibodies as well as a working bank of EVs known to be negative for all antibodies in question, which poses logistical difficulties.
The use of a lysis method is an established practice in EV analysis for identifying false positive events (55); however its utility as a replacement for isotypes in determining back ground fluorescence has not yet been described. In our research, we found that the lysis technique for gate placement worked as well or better than isotypes across all antibodies tested. It should be noted, however, that while using lysed samples for predicting background worked for our purposes, it may not necessarily be the best solution in all situations. One limitation of the lysis method is its inability to identify nonspecific binding of antibodies to EVs or other lipid vesicles such as chylomicrons. Furthermore, because lysis is not EV specific, some non EVs may become lysed and some small EVs may be resistant to lysis. For some, using a combination of the lysed sample and its isotype might work better than either alone for providing the best indication of background fluorescence for gate placement.
Washing After EV Staining
Removing unbound antibody after staining EVs often requires the use of lengthy, multi step washing procedures such as ultracentrifugation or sucrose fractionation. In an attempt to develop a protocol suited to high throughput sample analysis, we developed a technique using filters to wash EVs post staining. After staining with pre filtered anti body panels, EVs were originally added atop 0.2 lm centrifu gal filters with 300 mL PBS and centrifuged at low speed ($600g) for 10 30 sec. After testing a variety of PPP samples it was found that some required centrifugation at 800g for 2 5 min, which was the final protocol we adopted. The tops of the filters were resuspended in 400 mL PBS and analyzed using FCM. Figure 4 shows the results using antibodies for which resolution was improved after implementing post stain filtration to remove unbound antibody. Similar results were obtained with each antibody tested (data not shown). Assay reproducibility was tested across seven different markers in three experiments performed in triplicate on PPP from a single normal donor. Coefficients of variation (CVs) for non post stain filtered samples were 38.7, 15.6, 11.6, 28.9, 40.1, 12.8, and 2.4 for the markers CD14, CD16, CD19, CD152, CD235a, CD108, and CD41a, respectively. CVs for post stain filtered samples were 10.9, 40.7, 4.9, 11.3, 19.6, 16.4, and 7.5 for the same markers, which was not signifi cantly different from the samples that were not post stain fil tered (P 0.45).
Of the washing techniques currently used to remove unbound antibody post staining, all are time consuming, multi step procedures not suitable for high throughput analy sis. The most common methods, ultracentrifugation and sucrose fractionation, require long processing times and expensive equipment. Density gradient techniques described in the literature require 14 to 20 h centrifugations at forces of up to 192,000g (3, 70) . Here, we report the use of a novel filtra tion technique for reducing background fluorescence that is simple, fast, and effective. It should be noted that a significant limitation of this method is the loss of particles such as exo somes and small EVs that are small enough to pass through the 220 nm filter. This is an important consideration, as increasing evidence suggests that these very small EVs com prise the active/functional fraction of EVs as a whole, at least in some settings (68) . One solution to this limitation would be to recover the filtrate, couple the smaller EVs to beads to allow washing, and analyze bead bound small EVs; however, this would limit one's ability to measure co expression of multiple antigens on single EVs. While the increase in signal to noise ratio is of obvious benefit, the loss of smaller
Technical Note
EVs represents a significant limitation when considering any washing method (63) .
Effect of EV Concentration on Assay Sensitivity
It has been described that the flow cytometer can detect multiple small vesicles simultaneously illuminated by the cytometer's laser beam, counting them as a single event (50) . The phenomenon of coincidence detection would presumably be more pronounced in samples with higher concentrations of EVs, which could affect the number and type of events detected. Figure 5 shows the results of six different dilutions of PPP on EV detection using FCM. PPP from five healthy donors was stained for CD41a, then post stain filtered and resuspended in PBS. The samples were then serially diluted, and each was read for 60 sec on a flow cytometer. While the percentage of positive events was fairly unpredictable at very low EV concentrations, the number of positive events detected within a fixed time frame decreased proportionally with dilu tion factor, yielding approximately the same calculated num ber of CD41a1 events at each dilution. CVs of CD41a1 Figure 4 . Effect of post stain filtration. EV samples were acquired before and after post stain filtration of aliquots of the same sample. Briefly, stained EV samples were added atop a 0.22 mm filter, centrifuged, and the EVs remaining on top resuspended in 400 mL PBS and read using FCM. A: Representative flow cytometric dot plots showing effect of post stain filtration. Events shown are within the FSC/SSC EV gate. Values show percentages of positive events. EV samples were read before and after post stain filtration. Antibodies were added to EVs for 30 min then either diluted and read immediately using FCM (top row) or post stain filtered and then read (bottom row). Red arrows highlight the difference in background staining intensity. B: Effect of post stain filtration on seven CD markers using EVs from nor mal donors run in triplicate in three experiments. ***P < 0.0005, **P < 0.005., *P < 0.05. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Technical Note calculated counts were 5.4, 9.8, 9.6, 16.3, and 8.4 for the five donors across all the dilutions, comparable to the CV of 7.5 for replicates of one sample tested undiluted presented in Fig  ure 4 . These data show that across the concentration range of $100 100,000 positive events collected, the calculated count of EVs positive for CD41a did not vary substantially, implying that co incident particle detection did not play a significant role in detecting particles >200 nm at the concentrations tested.
Because coincidence detection is dependent on the num ber of surrounding EVs in a given sample, we thought it might be necessary to normalize the EV concentration of each sam ple prior to analyzing with FCM. However, we found no evi dence to support coincident particle counting in the dilution range we tested. In our dilution experiments we found that the percentages of positive events were equal and event counts were proportional to dilution factor between 1 3 10 5 and 1 3 10 6 EV/mL. With each 10 fold dilution, the number of positive events detected predictably dropped by a factor of 10. At higher dilutions, however, the percentages of events staining positive for a given marker became much less reliable due to a constant number of artifactual events in the denominator, Technical Note while event counts staining positive for a given marker remained consistent with dilution factor. Whereas percentage varied considerably at higher dilutions (due to the noise mak ing up a larger proportion of the denominator at higher dilu tions), the number of positive events was consistent and reliable. With the analysis of these dilution experiments, we gained a new understanding of our results and learned that the best parameter to record was the number of positive events in a set time period, not percentage of positive EV events. With this finding, we changed our recording methods to place new emphasis on number of positive events collected within a fixed time frame, rather than percentage of the total EV population collected being positive for the marker in ques tion. Because of the influence of background noise at low EV concentrations, we concluded that counting the number of positive events within a fixed time frame yielded more repro ducible results than using the percentage of the total EV popu lation being positive for the marker in question. The CVs in these dilution experiments (between 5.4 and 16.3, mean 9.9) were similar to the CV we observed in our reproduci bility experiments (7.5), thus concentration is unlikely to play a huge role in our sample to sample variability.
CONCLUSION
Here, we have presented optimization techniques that are especially well suited for analyzing EVs from a high volume of clinical samples. In particular, we showed that 1) filters are a good alternative to centrifugation for removing antibody aggregates before staining, 2) lysed samples are a useful alter native to isotypes for setting gates to exclude background fluorescence, 3) filters can be used to "wash" samples post staining thus providing a faster alternative to ultracentrifuga tion and sucrose gradient fractionation, and 4) normalization of EV concentration prior to staining is unnecessary in the concentration range we examined. Methods for EV analysis, while considerably improved over the last decade, are still a work in progress. Ultimately, the best methods for analyzing EVs will depend on the individual lab's needs and tools avail able to the researcher. The techniques described here will assist with eliminating the antibody aggregates commonly found in commercial preparations, increasing signal to noise ratio, and setting gates in a rational fashion that minimizes detection of background fluorescence.
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Introduction
Extracellular Vesicles (EVs) are small, membrane-derived vesicles found in bodily fluids that are highly involved in cell-cell communication and help regulate a diverse range of biological processes. Analysis of EVs using flow cytometry (FCM) has been notoriously difficult due to their small size and lack of discrete populations positive for markers of interest. Methods for EV analysis, while considerably improved over the last decade, are still a work in progress. Unfortunately, there is no one-size-fits-all protocol, and several aspects must be considered when determining the most appropriate method to use. Presented here are several different techniques for processing EVs and two protocols for analyzing EVs using either individual detection or a bead-based approach. The methods described here will assist with eliminating the antibody aggregates commonly found in commercial preparations, increasing signal-to-noise ratio, and setting gates in a rational fashion that minimizes detection of background fluorescence. The first protocol uses an individual detection method that is especially well suited for analyzing a high volume of clinical samples, while the second protocol uses a bead-based approach to capture and detect smaller EVs and exosomes.
EVs, also known as microparticles, are small, membrane-derived vesicles found in bodily fluids that are involved in cell-cell communication and help regulate a diverse range of biological processes 1 . Through expression of various surface markers and/or direct transfer of biological material, EVs are able to alter the function of recipient cells to play either activating or suppressing roles in intercellular communication [2] [3] [4] . Clinically, platelet-derived EVs are known to have strong anticoagulant activity 5 , while others have been shown to contribute to a wide range of conditions, from promoting tumor metastasis 6 to protecting against disease 7 . EVs can be classified into smaller categories of cell-derived vesicles such as exosomes and microvesicles (MVs), depending on their size and mechanism of generation 8 . The nomenclature of cell-derived vesicle subpopulations continues to be a topic of ongoing debate 8, 9 , however, exosomes are generally described as small, 40 to 100 nm particles derived from endosomal fusion with the plasma membrane, while MVs are larger 100 to 1,000 nm particles formed by shedding of the plasma membrane 10 . Here, the general term "EVs" will be used to refer to all types of extracellular biological vesicles released by cells.
Isolation of EVs from whole blood is a multi-step procedure and many different processing variables have been shown to affect EV content, including storage temperature and duration 11, 12 , anticoagulant/preservative used 13 and centrifugation method used 14 . A need for standardization of these variables has led to recommendations by the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee (ISTH SSC) for proper blood processing and EV isolation procedures 15, 16 , yet there exists no consensus among researchers on the optimal protocol to use 12 . Most agree, however, that tightly controlled pre-analytical variables are crucial for accurate and reproducible data.
In order to analyze EVs, researchers have utilized various methods, including transmission electron microscopy 17 , scanning electron microscopy 18, 19 , atomic force microscopy, dynamic light scattering 20, 21 and western blotting 22, 23 . While FCM is the method of choice for many researchers 9,24-26 due to its high throughput capabilities, analysis of EVs using FCM has been notoriously difficult due to their size and lack of discrete positive populations [27] [28] [29] [30] [31] [32] . fewer number of antigens per particle and 2) limited feas bility of post-stain washing, which is necessary to reduce background fluorescence. Common challenges among researchers include signals arising from immunoglobulin aggregates 27, 28 and self-aggregation of antibodies 29 . Furthermore, the long processing times and lengthy washing/isolation procedures used by many of the current protocols 33, 34 require multi-day time commitments to analyze a small number of samples, making them less than ideal for high throughput applications. Some researchers forgo a wash step altogether, rendering traditionally used FCM negative controls such as fluorescence minus one (FMO) and ant body isotypes useless for accurately assessing background fluorescence 30 .
Our protocols address three common problems that can impede proper FCM analysis of EVs: signals arising from ant body aggregates and other non-vesicles, difficulty in removing unbound antibody, and lack of discernible positive populations. The techniques described here will assist with eliminating the antibody aggregates commonly found in commercial preparations, increasing signal-to-noise ratio, and setting gates in a rational fashion that minimizes detection of background fluorescence. Two different detection methods are presented here: the first protocol uses an individual detection method that is especially well suited for analyzing a high volume of clinical samples, while the second protocol uses a beadsbased approach to capture and detect smaller EVs and exosomes.
detergent-resistant EVs. Figure 3 shows expected results using the bead-based detection method. Unlike the individual detection method, these data cannot/should not be viewed in bi-parameter plots. In the upper dot plots, no separation between the positive and negative populations exist, and events appear in the double positive quadrants even though they aren't normally found on the same cell types due to the fact that both types of EVs will bind to a single bead. For the bead-based detection method, data are best analyzed using histogram overlays with the negative control (depicted underneath the dot plots). Positivity is measured using a marker's MFI (mean fluorescence intensity) and compared directly with that of the negative control. If a sample is positive for the marker in question, its MFI will be higher than the negative control. The negative control for the bead method is simply beads blocked with BSA (no EVs added), which have been stained with the same antibodies and washed alongside the EV-coated beads. A comparison of expected results using the two methods can be seen in Figure 4 .
The ability of the individual detection assay to properly assess EV phenotypes relies heavily on correct gating to separate Ab-positive events from background fluorescence. Therefore, it is critical to choose a negative control that most appropriately mimics/predicts background fluorescence for a given sample. When stained EVs are not washed before reading, commonly used negative controls (e.g., isotypes) fail to accurately predict background fluorescence for all markers ( Figure 5A ). In these cases, if washing is not an option, lysed samples tend to work better for predicting background fluorescence. However, when stained EVs are washed before reading (using centrifugal filtration, in this case), both negative controls (isotypes and lysed samples) work well for predicting background fluorescence of a sample ( Figure 5A ). It should be noted, however, that while all negative controls "work," lysed controls are preferred because they provide additional information about a sample (e.g., the presence of detergent-resistant, non-vesicle-related events and/or aggregates) that can result in non-EV positive signals and improperly inflate Ab counts. Furthermore, isotype controls can sometimes be unreliable, even in washed samples, as shown in Figure 5B , where the stained sample has fewer positive events than the same sample stained with matched isotype control antibodies.
Without thorough removal of unbound antibody, FCM dot plots of some EV markers are nearly impossible to interpret, appearing as clouds of dimly fluorescent particles indistinguishable from their highly fluorescent backgrounds ( Figure 6 , top plot). Washing stained samples using centrifugal filters enhances the separation between background and positive marker signals ( Figure 6 , bottom plot); however, small EVs and exosomes may be lost through the pores of the filter.
The use of a detergent lysis step reveals positive, vesicle-mimicking events from immune complexes and protein aggregates 21 . When PPP is analyzed using individual detection, encountering positive events that do not disappear with lysis is a fairly often occurrence. These detergentresistant events often appear as suspicious, highly fluorescent diagonal signals in both single parameter and biparameter plots (Figure 7) . Clinically, these protein complexes and/or insoluble immune complexes are more prevalent in patients afflicted with various diseases 21 , such as rheumatoid arthritis 28 , nephrotic syndrome 19 , and systemic lupus erythematosus 29 . Therefore, depending on the objective of the research, one may wish to include or remove them from the analysis.Another way diagonal signals can form is by vortexing the samples, particularly after the addition of the lysis reagent (Figure 8) . Samples should always be mixed up and down by pipet to prevent the formation of aggregates. 
Discussion
Tw differen protocol fo th isolation treatmen an analysi o EV wer presented usin eithe a individua detectio o bead-based approach Selectin th mos appropriat metho t us i no alway straightforwar an require a understandin o th sampl bein tested a wel a th individua subpopulation o interest Furthermore th sensitivit o th cytomete use fo acquisitio mus b considere when choosin th mos appropriat method Oftentime ther i n singl bes protoco t use rather combinatio o method provide more informatio abou sampl tha an on metho alone Ideally severa differen isolatio an detectio technique shoul b evaluate first i orde t develo tailore protoco tha take int consideratio individua cytomete performanc wit respec t th specifi E population bein studied Alternativ isolatio technique includ ultracentrifugation sucros densit fractionation immunomagneti bea separation, chromatography an affinit purification 12 whil alternativ detectio method includ scannin electro microscopy transmissio electron . By combining different techniques, the methods presented here can be adapted in order to create protocols best suited for studying various EV populations of interest.
In general, individual detection of EVs using FCM works well for analyzing larger EVs but loses sensitivity as EVs get smaller. While individual detection is more consistent in detecting larger EVs, bead-based detection is less sensitive in detecting larger EVs and more sensitive for exosomes. Larger EVs can be washed easily via post-stain filtration and detected singly via FCM. Smaller EVs and exosomes, on the other hand, are not detected well individually using FCM and are much more difficult to wash post-staining. The bead-capture protocol resolves both of these issues, allowing EVs to be easily washed and multiple EVs to be measured together to create larger positive signals detectable by FCM. However, there are drawbacks associated with using this method, as outlined in Table 1 .
When working with a less sensitive cytometer, the capacity for individual detection is limited. Prior to EV analysis, the sensitivity of the cytometer should be determined using a mixture of bead sizes ranging from 0.1-1.0 µm. Failure of the cytometer to detect a majority of particles below 1.0 µm would necessitate the use of the bead-based protocol. Highly expressed markers are easily detected using either protocol. Rarer populations are sometimes easier to detect using the single particle detection protocol rather than the bead capture protocol, however, this can vary depending on such variables as: the brightness of the fluorochrome, the sample's EV:bead ratio, and the size of the EV bearing the rare cell surface marker. Detection of multiple markers on a single particle necessitates the use of the individual detection method. The bead-based method is not capable of individual EV detection. Therefore, the bead-based protocol will yield data that are more qualitative in nature, while the individual detection method will give more quantitative data.
Additional isolation techniques must be utilized whenever EVs are needed for downstream applications. EVs used in functional assays should be ultracentrifuged using the 3-step differential centrifugation protocol, since the soluble serum proteins in plasma can affect functional experimental outcomes. For characterization of EVs, however, ultracentrifugation is not recommended, since this added step may affect EV quality and quantity due to the high forces imparted on the particles 12 .
The individual detection protocol contains several key steps optimized for high-throughput testing, including: 1) the implementation of centrifugal filters for the quick and effective removal of positive events caused by Ab aggregates, 2) the use of filters as a more practical alternative to ultracentrifugation or sucrose gradient fractionation for washing unbound Ab from EV samples post-staining, and 3) utilization of detergent lysis as a negative control, which not only reveals positive events caused by non-EVs but provides a good approximation of background fluorescence to distinguish positive from negative populations for drawing gates. The individual detection protocol is recommended whenever a large number of samples needs testing as it can be performed in a single day, whereas the bead-based method requires an overnight incubation.
The negative controls in each protocol have different advantages and disadvantages depending on which detection method is used. One benefit of using the bead-based assay is that the same monoclonal antibodies can be used for negative and positive tubes and the same negative control can be used for all samples. The individual detection method, on the other hand, requires separate controls to be read for each sample tested. The negative control used by the individual detection protocol uses lysed samples, which do not require the use/consumption of additional ant bodies but do require that each tube be read a second time after addition of the lysing agent. The lysed controls have the added benefit of being able to identify the proportion of positive signal that can be attributed to non-vesicle-related events such as immune complexes 21 . The bead-based assay does not have this ability todistinguish between positive signals arising from true EVs and those arising from nonvesicles.
Limitations of the technique
While there is no standardized method for the isolation of EVs, differential centrifugation is a widely used technique among EV researchers. The differential centrifugation method descr bed here is based on common protocols for isolating PPP, which typically require an initial centrifugation between 1,200-1,500 x g for 10-20 min to remove cells, followed by a second centrifugation between 10,000-13,000 x g for 10-30 min to remove platelets 35 . The protocol described herein uses a centrifugation at 1,500 x g for 10 min followed by a centrifugation at 13,000 x g for 10 min. While higher forces of 25,000-100,000 x g are typically required to pellet EVs, some of the larger EVs may be removed with the differential centrifugation protocol we have presented.
Up to 90% of EVs detected by FCM are lost with one hour ultracentrifugation at 100,000 x g (data not shown). Longer centrifugation times should be considered, albeit cautiously, as this may adversely impact the sample's composition. If additional processing is needed for characterization studies, filtration can be performed after the 2-step centrifugation (before staining) to further fractionate samples based on particle size. Similar to ultra-centrifugation, filtration can result in a loss of up to 50% of positive marker events and up to 90% of total particles detected by FCM (data not shown). While the increase in signal-to-noise ratio is of obvious benefit, the loss of smaller EVs represents a significant limitation when considering any washing or isolation method.
Finally, the anticoagulant used (e.g., heparin, ACD, ethylenediaminetetraacetic acid (EDTA), etc.) during blood collection may impact the quality and quantity of EV content. While ACD has proven to be a good and reliable anticoagulant for our studies, testing multiple solutions is recommended to ensure that the most suitable anticoagulant for the application is chosen. This is especially important when EVs will be used in downstream assays where the anticoagulant used can affect the outcome. For example, some anticoagulants (e.g., EDTA and heparin) are known to interfere with PCR reactions while others (e.g., theophylline, adenosine and dipyridamole) have been shown to inhibit EV release from platelets 12 .
Methods for EV analysis, while considerably improved over the last decade, are still a work in progress. Ultimately, the best methods for analyzing EVs will depend on the research being conducted and tools available to the researcher.
